Who are CAIV-T's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FluMist trivalent (2015-2016), FluMist Quadrivalent (2017-2018), Intranasal Influenza Live Attenuated Vaccine, Pandemic Influenza Vaccine, CAIVT, Q/LAIV (MEDI3250).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/caiv-t.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CAIV-T — Competitive Intelligence Brief

CAIV-T (CAIV-T) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated influenza vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

CAIV-T (CAIV-T) — MedImmune LLC. CAIV-T is a live attenuated influenza vaccine administered intranasally that stimulates mucosal and systemic immune responses against influenza A and B viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CAIV-T TARGET	CAIV-T	MedImmune LLC	phase 3	Live attenuated influenza vaccine
FluMist trivalent (2015-2016)	FluMist trivalent (2015-2016)	MedImmune LLC	marketed	Live attenuated influenza vaccine
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	MedImmune LLC	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus
Intranasal Influenza Live Attenuated Vaccine	Intranasal Influenza Live Attenuated Vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	Live attenuated influenza vaccine
Pandemic Influenza Vaccine	Pandemic Influenza Vaccine	Altimmune, Inc.	phase 3	Live attenuated influenza vaccine (LAIV)
CAIVT	CAIVT	MedImmune LLC	phase 3	Live attenuated influenza vaccine
Q/LAIV (MEDI3250)	Q/LAIV (MEDI3250)	MedImmune LLC	phase 3	Live attenuated influenza vaccine (LAIV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated influenza vaccine class)

MedImmune LLC · 5 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAIV-T — Competitive Intelligence Brief. https://druglandscape.com/ci/caiv-t. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab